The lumbar degenerative disc disease market is projected to demonstrate substantial growth in the coming years across the 7MM. The market landscape is witnessing active participation from key ...

Phase I/II data of IDCT (rebonuputemcel), a cell therapy in development for chronic and progressive lumbar degenerative disc disease and one that has both regenerative medicine advanced therapy and ...

Receives FDA acceptance on Phase III clinical protocols for parallel pivotal and confirmatory trials Achieves alignment with FDA on Chemistry, Manufacturing, and Controls (CMC) aspects of Phase ...

Objectives: To observe the prevalence of lumbar intervertebral disc degeneration in elite athletes as compared with published literature of changes seen in non-athletes—that is, normal population.

Cite this: Artificial Disc Replacement for Degenerative Disc Disease of the Cervical Spine: A Technology Assessment - Medscape - Jun 01, 2010. Abstract and Introduction Background ...

DiscGenics Announces US FDA Approval to Proceed with Phase III Clinical Evaluation of Allogeneic, Injectable Disc Progenitor Cell Therapy for Symptomatic Lumbar Degenerative Disc Disease PR ...

Emerging Degenerative Disc Disease therapies in the different phases of clinical trials are-SB-01, BRTX-100, Rexlemestrocel-L, Lorecivivint, CWT 002, AMG0103, IDCT, KUR 113, BRTX-100, AGA111, and ...

The Fast Track designation is supported by blinded preliminary data from a randomized, double-blind phase 2 trial (ClinicalTrials.gov Identifier: NCT04042844) that evaluated a single dose of BRTX ...